Clinical Trial Update: A Study of KRN23 in Adult and Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia [Phase 3]

View source ↗

Summary

Phase 3 trial update for KRN23 in adults and children with X-linked hypophosphatemic rickets/osteomalacia (XLH) completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteomalacia
• X-linked Hypophosphatemic Rickets

Drugs mentioned

• KRN23 (burosumab)

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: XLH | Phase 3 | Status: COMPLETED